Targeted overexpression of ornithine decarboxylase enhances beta-adrenergic agonist-induced cardiac hypertrophy.
These studies were designed to determine the consequences of constitutive overexpression of ornithine decarboxylase (ODC) in the heart. Induction of ODC is known to occur in response to agents that induce cardiac hypertrophy. However, it is not known whether high ODC levels are sufficient for the development of a hypertrophic phenotype. Transgenic mice were generated with cardiac-specific expression of a stable ODC protein using the alpha-myosin heavy-chain promoter. Founder lines with >1000-fold overexpression of ODC in the heart were established, resulting in a 50-fold overaccumulation of putrescine, 4-fold elevation in spermidine, a slight increase in spermine and accumulation of large amounts of cadaverine compared with littermate controls. Despite these significant alterations in polyamines, myocardial hypertrophy, as measured by ratio of heart to body weight, did not develop, although atrial natriuretic factor RNA was slightly elevated in transgenic ventricles. However, stimulation of beta-adrenergic signalling by isoproterenol resulted in severe hypertrophy and even death in ODC-overexpressing mice without further altering polyamine levels, compared with only a mild hypertrophy in littermates. When beta1-adrenergic stimulation was blocked by simultaneous treatment with isoproterenol and the beta1 antagonist atenolol, a significant, although reduced, hypertrophy was still present in the hearts of transgenic mice, suggesting that both beta1 and beta2 adrenergic receptors contribute to the hypertrophic phenotype. Therefore these mice provide a model to study the in vivo co-operativity between high ODC activity and activation of other pathways leading to hypertrophy in the heart.
Shantz
L M
LM
Department of Cellular and Molecular Physiology H166, P.O. Box 850, The Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA. lms17@psu.edu
Feith
D J
DJ
Pegg
A E
AE
D000318:Adrenergic beta-Agonists / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D001262:Atenolol / Q000494:pharmacology; D015139:Blotting, Southern; D002103:Cadaverine / Q000096:biosynthesis; D006332:Cardiomegaly / Q000201:enzymology*; D006984:Hypertrophy / Q000201:enzymology; D007150:Immunohistochemistry; D007545:Isoproterenol / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D008957:Models, Genetic; D009206:Myocardium / Q000201:enzymology; D009955:Ornithine Decarboxylase / Q000096:biosynthesis*; D011401:Promoter Regions, Genetic; D011700:Putrescine / Q000096:biosynthesis; D012333:RNA, Messenger / Q000378:metabolism; D013095:Spermidine / Q000096:biosynthesis; D013096:Spermine / Q000096:biosynthesis; D014018:Tissue Distribution
D000318:Adrenergic beta-Agonists; D012333:RNA, Messenger; D013096:Spermine; D001262:Atenolol; D009955:Ornithine Decarboxylase; D007545:Isoproterenol; D002103:Cadaverine; D013095:Spermidine; D011700:Putrescine